Acceleron P (XLRN)

173.95
+0.20(+0.12%)
After Hours
174.05
+0.10(+0.06%)
- Real-time Data
  • Volume:
    196,689
  • Bid/Ask:
    173.96/174.85
  • Day's Range:
    173.50 - 174.42

XLRN Overview

Prev. Close
173.75
Day's Range
173.5-174.42
Revenue
101.13M
Open
174.23
52 wk Range
99.98-189.99
EPS
-3.7
Volume
196,689
Market Cap
10.64B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
833,697
P/E Ratio
-
Beta
0.14
1-Year Change
59.09%
Shares Outstanding
61,147,922
Next Earnings Date
Nov 10, 2021
What is your sentiment on Acceleron P?
or
Market is currently closed. Voting is open during market hours.

Acceleron P News

Acceleron P Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyBuyStrong BuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Acceleron P Company Profile

Acceleron P Company Profile

Employees
312

Acceleron Pharma Inc. is a biopharmaceutical company. The Company is focused on its research, development, and commercialization efforts in pulmonary and hematologic diseases. Its research is focused on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta) protein superfamily. The Company's product pipeline includes Sotatercept, ACE-1334 and REBLOZYL (luspatercept-aamt). Its lead pulmonary program, Sotatercept, is an activin receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC).

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.